Russian pharmaceutical company begins trials of cancer drug analog
A Russian pharmaceutical company has announced the start of clinical trials for a new medicinal drug. This treatment is intended for oncological diseases and is set to become an analog of the well-known foreign drug "Xalkori," which is produced by Pfizer.
The primary goal of the current trials is to prove the bioequivalence of the Russian drug to the original. This means that scientists must confirm that the new Russian analog acts on the patient's body as effectively and safely as the original medication. The study is an important step toward ensuring the availability of therapy for Russian patients.
The drug "Xalkori" belongs to the category of targeted therapy, which is aimed at fighting specific types of tumors. The emergence of a domestic analog could significantly simplify access to treatment for people suffering from severe diseases and reduce dependence on foreign drug supplies.
In the event of the successful completion of all testing stages and the receipt of necessary approvals, the company will be able to begin mass production of the drug. This event is part of a state program for the development of the pharmaceutical industry and the import substitution of vital medications in Russia.